The motivation of testing fish oil as the dietary supplements could be derived from the ongoing clinical trial activities evaluating the agonists of GABRG-3, GABRA-4, DRD-5, and THRB (all were elevated by FD), and the antagonists of GABRA-5 (suppressed by FD) for treating depression (www.clinicaltrials.gov). This evidence concerns the gene GABRA4 and depressive disorder.